MagicMed Raises $1.6M to Launch Psychedelic Drug Discovery Platform
September 2, 2020
Ryan Allway September 2nd, 2020 Psychedelics, Top Story MagicMed Industries Inc. raised roughly $1.6 million in an oversubscribed private placement to develop Psybrary™—a proprietary drug discovery platform for the psychedelics industry. Using its deep expertise in molecular derivatives, the company aims to develop a library of derivative variant molecules... Read more
MagicMed Industries Closes Oversubscribed Private Placement for $1,642,880 with Mackie Research Capital Corporation
September 2, 2020
Ryan Allway September 2nd, 2020 Psychedelics, Top News CALGARY, AB, Sept. 2, 2020 /CNW/ – MagicMed Industries Inc. (“MagicMed” or the “Company“) is pleased to announce that it has completed, and oversubscribed, its previously announced brokered private placement (the “Offering“) for gross proceeds of $1,642,880. Pursuant to the Offering, the Company issued 6,571,520... Read more
Mind Medicine Australia Submits Australia-First Application for the Rescheduling of Psilocybin and MDMA
September 1, 2020
Ryan Allway September 1st, 2020 Psychedelics Mind Medicine Australia has submitted Australia’s first applications to the Therapeutic Goods Administration (TGA) to reschedule Psilocybin and MDMA so that they can be more easily used as part of clinical therapies for the treatment of major classes of mental illness. The rescheduling... Read more
Numinus Files Restated Financial Reports
August 27, 2020
Ryan Allway August 27th, 2020 Psychedelics Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI) announces that as a result of a review by the Company’s auditors in connection with its recently announced prospectus, the Company, on August 24, 2020, has filed restated financial statements (the “Amended Financial Statements”) together... Read more
NeonMind Ready to Launch Four Mushroom Coffee Blends
August 21, 2020
Ryan Allway August 21st, 2020 Psychedelics Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:BOSQF) (FE:YG3) (“Better”) announces that subsidiary Neonmind Biosciences (“NeonMind”) has completed final product development for four unique Ayurveda-inspired and botanical-enhanced mushroom coffee blends which are now moving into the mixing stage with a co-packer. The coffees are fair trade... Read more
Ryan Allway August 18th, 2020 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – August 17, 2020) – Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or the “Company“) is pleased to announce that that it has completed the previously announced acquisition (the “Transaction“) of Psychedelic Science Corp.(“PSC“), as per our press... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
What Are Functional Mushrooms?
August 17, 2020
Ryan Allway August 17th, 2020 App, Exclusive, Psychedelics, Top Story Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit,... Read more
Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19
August 14, 2020
Ryan Allway August 14th, 2020 Psychedelics, Top News August 14, 2020 08:44 ET | Source: Revive Therapeutics Ltd. TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs... Read more
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results
August 14, 2020
NEW YORK, Aug. 14, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the... Read more
